The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted TherapiesOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This longitudinal study tracked gut microbiome stability in Parkinson's disease over one year and tested whether microbiome profiles predict disease progression. Stool samples underwent 16S rRNA V3-V4 amplicon sequencing at 0, 6, and 12 months. Faster versus slower progression was defined by changes in levodopa equivalent dose and motor severity scores. A separate group starting device-assisted therapies was followed for a year after initiation. Machine learning models combined microbiota and nutritional data.
Who was studied?
The cohort was 74 Parkinson's disease patients and 74 household controls in Sydney, Australia, sampled at three time points. Patients had a mean age of 67.2 years and mean disease duration of 8.6 years. Controls were spouses or close relatives sharing the same household and diet. A separate group of 19 patients initiating deep brain stimulation or levodopa-carbidopa intestinal gel was evaluated over 12 months.
What were the most important findings?
Parkinson's patients showed a persistent underrepresentation of short-chain-fatty-acid-producing, butyrogenic bacteria, including genera of the Lachnospiraceae family, across all three time points. Alpha and beta diversity differed significantly from controls (both p less than 0.01). Faster and slower progressors differed in microbiome composition, but no indicator taxon persisted across all time points. Device-assisted therapies produced variable, non-persistent microbiome effects. Adding dietary protein intake raised progression prediction from an area under the curve of 0.58 to 0.64.
What are the greatest implications of this study?
The findings support a persistently altered gut microbiome in Parkinson's disease, marked by reduced butyrate-producing potential, which may relate to gut leakiness and inflammation. Combining microbiome and dietary data improved prediction of who progresses faster. The associations do not prove causation. The controls were not perfectly matched for age and sex, and progression was hard to define. Larger cohorts with longer follow-up are needed to confirm these microbial trends.